2023-04
喜讯 | 博生吉医药TAA06注射液顺利完成I期临床试验的首例患者回输
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co. Ltd is a biotech company focusing on developing leading-edge cellular therapeutics. The company is committed to developing CAR-related therapeutic and analytical antibodies, novel CAR- products, and allogeneic cellular therapies. The company has developed a comprehensive pipeline of products and a world-leading allogeneic off-the-shelf UCAR-Vδ1 T-cell R&D platform.
PersonGen.Anke Cellular Therapeutics Co., Ltd.
PersonGen-Anke Cellular Therapeutics Co., Ltd. is a subsidiary company and the manufacturing base of PersonGen BioTherapeutics. The company is equipped with the global-leading fully-automated, closed manufacturing system for cellular therapeutics. It also has the most advanced facilities for the manufacturing of clinical-grade DNA plasmids and lentiviruses. The company has developed fully validated manufacturing processes of CAR-T, allogeneic γδT and UCAR-γδT products.
Read More
PersonGen BioTherapeutics is one of the first company in China focusing on the development of CAR-T and other cellular immunotherapies.
We are driven by our values “Care for People, Cure Every Patient”, and is committed to being the world leader on developing allogeneic cellular therapies against tumors and autoimmunity diseases.
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
自2015年药审改革以来,2024年已步入第十个年头。在这样一个创新驱动发展的时代浪潮中,医药行业的创新力量正以前所未有的速度推动着健康产业...
近日,安徽省工业和信息化厅对2024年(第33批)拟认定安徽省企业技术中心的企业名单进行公示,经企业申报、各市初审推荐、初评、专家评审和综合...
2024年11月14日至17日,国际细胞与免疫治疗(CTI)大会在中国杭州盛大举行,汇聚了全球细胞治疗和免疫治疗领域的顶尖专家、学者和行业领...
2024年11月8日,安徽省工业和信息化厅对2024年省级专精特新企业通过名单进行了公示,博生吉安科细胞技术有限公司成功登榜,被认定为202...
Conceptual Pilot Study, Patient Recruitment
Read More